Heart failure resulting from cancer treatment: still serious but an opportunity for prevention
- PMID: 29973341
- DOI: 10.1136/heartjnl-2018-313493
Heart failure resulting from cancer treatment: still serious but an opportunity for prevention
Keywords: heart failure.
Conflict of interest statement
Competing interests: ARLhas received speaker, advisory board, consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Clinigen Group, Takeda, Roche, Eli Lily,Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals and Boehringer Ingelheim.
Comment on
-
Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy.Heart. 2019 Jan;105(1):34-41. doi: 10.1136/heartjnl-2018-313234. Epub 2018 May 15. Heart. 2019. PMID: 29764969 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical